{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:20:48Z","timestamp":1792794048918,"version":"4.5.0"},"reference-count":322,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Lipid Research"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.plipres.2023.101238","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T12:18:50Z","timestamp":1685017130000},"page":"101238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"special_numbering":"C","title":["Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances"],"prefix":"10.1016","volume":"91","author":[{"given":"Giovanni","family":"Musso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Saba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Cassader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gambino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.plipres.2023.101238_bb0005","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.plipres.2018.06.003","article-title":"Contemporary lipidomic analytics: opportunities and pitfalls","volume":"71","author":"Giles","year":"2018","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb0010","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1194\/jlr.R300004-JLR200","article-title":"Global analyses of cellular lipidomes directly from crude extracts of biological samples by ESI mass spectrometry: a bridge to lipidomics","volume":"44","author":"Han","year":"2003","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb0015","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology."},{"key":"10.1016\/j.plipres.2023.101238_bb0020","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nrd.2015.3","article-title":"Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies","volume":"15","author":"Musso","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.plipres.2023.101238_bb0025","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1053\/j.gastro.2017.01.003","article-title":"Changes in the prevalence of hepatitis C virus infection, non-alcoholicsteatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation","volume":"152","author":"Goldberg","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.plipres.2023.101238_bb0030","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/hep.21655","article-title":"Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis","volume":"45","author":"Yamaguchi","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2023.101238_bb0035","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/hep.21763","article-title":"A Lipidomic analysis of nonalcoholic fatty liver disease","volume":"46","author":"Puri","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2023.101238_bb0040","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/hep.23229","article-title":"The plasma lipidomic signature of nonalcoholic steatohepatitis","volume":"50","author":"Puri","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2023.101238_bb0045","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1194\/jlr.M007096","article-title":"Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"51","author":"Feldstein","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb0050","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1021\/pr1002593","article-title":"Liquid chromatography-mass-spectrometry-based-parallel-metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease","volume":"9","author":"Barr","year":"2010","journal-title":"J Proteome Res"},{"key":"10.1016\/j.plipres.2023.101238_bb0055","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1021\/pr201223p","article-title":"Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression","volume":"11","author":"Barr","year":"2012","journal-title":"J Proteome Res"},{"key":"10.1016\/j.plipres.2023.101238_bb0060","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1194\/jlr.P056002","article-title":"Biomarkers of NAFLD progression: a lipidomics approach to an epidemic","volume":"56","author":"Gorden","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb0065","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1194\/jlr.P055640","article-title":"Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis","volume":"56","author":"Loomba","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb0070","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.cgh.2016.05.046","article-title":"Noninvasive detection of nonalcoholic steatohepatitis using clinical markers and circulating levels of lipids and metabolites","volume":"14","author":"Zhou","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.plipres.2023.101238_bb0075","doi-asserted-by":"crossref","DOI":"10.1038\/srep46658","article-title":"Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients","volume":"7","author":"Chiappini","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.plipres.2023.101238_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2022.101165","article-title":"Polyunsaturated fatty acids and fatty acid-derived lipid mediators: recent advances in the understanding of their biosynthesis, structures, and functions","volume":"86","author":"Dyall","year":"2022","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb0085","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/hep.28953","article-title":"Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease","volume":"65","author":"Hall","year":"2017","journal-title":"Hepatology."},{"key":"10.1016\/j.plipres.2023.101238_bb0090","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1053\/j.gastro.2022.03.004","article-title":"Postprandial plasma lipidomics reveal specific alteration of hepatic-derived diacylglycerols in nonalcoholic fatty liver disease","volume":"162","author":"Velenosi","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.plipres.2023.101238_bb0095","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/s12951-022-01540-4","article-title":"Lipidomic identification of urinary extracellular vesicles for non-alcoholic steatohepatitis diagnosis","volume":"20","author":"Zhu","year":"2022","journal-title":"J Nanobiotechnol"},{"issue":"4","key":"10.1016\/j.plipres.2023.101238_bb0100","doi-asserted-by":"crossref","first-page":"607","DOI":"10.14309\/ajg.0000000000000154","article-title":"Angiotensin II Type 1 Receptor rs5186 Gene Variant Predicts Incident NAFLD and Associated Hypertension: Role of Dietary Fat-Induced Pro-Inflammatory Cell Activation","volume":"114","author":"Musso","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.plipres.2023.101238_bb0105","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.plipres.2012.11.002","article-title":"Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis","volume":"52","author":"Musso","year":"2013","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb0110","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.plipres.2023.101238_bb0115","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1096\/fj.14-249763","article-title":"Plasma membrane phospholipase A2 controls hepatocellular fatty acid uptake and is responsive to pharmacological modulation: implications for nonalcoholic steatohepatitis","volume":"28","author":"Stremmel","year":"2014","journal-title":"FASEB J"},{"key":"10.1016\/j.plipres.2023.101238_bb0120","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.bbrc.2019.11.158","article-title":"High-fat diet-derived free fatty acids impair the intestinal immune system and increase sensitivity to intestinal epithelial damage","volume":"522","author":"Tanaka","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.plipres.2023.101238_bb0125","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.fct.2018.11.011","article-title":"The functional role of Bax\/Bak in palmitate-induced lipoapoptosis","volume":"123","author":"Zhang","year":"2019","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.plipres.2023.101238_bb0130","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/hep.29689","article-title":"New insights into the role and mechanism of c-Jun-N-terminal kinase signaling in the pathobiology of liver diseases","volume":"67","author":"Win","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2023.101238_bb0135","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.cmet.2014.06.010","article-title":"The PPAR-alpha-FGF21 hormone axis contributes to metabolic regulation by the hepatic JNK signaling pathway","volume":"20","author":"Vernia","year":"2014","journal-title":"Cell Metab"},{"key":"10.1016\/j.plipres.2023.101238_bb0140","doi-asserted-by":"crossref","first-page":"44612","DOI":"10.1038\/srep44612","article-title":"Effect of modulation of PPAR-\u03b3 activity on Kupffer cells M1\/M2 polarization in the development of non-alcoholic fatty liver disease","volume":"7","author":"Luo","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.plipres.2023.101238_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0226940","article-title":"Monounsaturated fatty acids protect against palmitate-induced lipoapoptosis in human umbilical vein endothelial cells","volume":"14","author":"Lee","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.plipres.2023.101238_bb0150","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.plipres.2012.10.004","article-title":"Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease","volume":"52","author":"Leamy","year":"2013","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb0155","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.plipres.2011.12.004","article-title":"Novel qualitative aspects of tissue fatty acids related to metabolic regulation: lessons from Elovl6 knockout","volume":"51","author":"Shimano","year":"2012","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb0160","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.chemphyslip.2015.08.018","article-title":"Recent progress in the discovery and development of stearoyl-CoA desaturase inhibitors","volume":"197","author":"Uto","year":"2016","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/j.plipres.2023.101238_bb0165","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1248\/bpb.b12-00702","article-title":"A novel inhibitor of stearoyl-CoA-desaturase-1 attenuates hepatic lipid accumulation, liver injury and inflammation in model of nonalcoholic steatohepatitis","volume":"36","author":"Kurikawa","year":"2013","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.plipres.2023.101238_bb0170","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.cgh.2014.04.038","article-title":"The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease","volume":"12","author":"Safadi","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.plipres.2023.101238_bb0175","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1002\/hep4.2053","article-title":"Reduction in gut-derived MUFAs via intestinal stearoyl-CoA desaturase 1 deletion drives susceptibility to NAFLD and hepatocarcinoma","volume":"6","author":"Ducheix","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.plipres.2023.101238_bb0180","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/hep.30674","article-title":"MRI assessment of treatment response in HIV-associated NAFLD: a randomized trial of a stearoyl-coenzyme-A-desaturase-1inhibitor (ARRIVE Trial)","volume":"70","author":"Ajmera","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2023.101238_bb0185","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.cmet.2007.12.003","article-title":"Metabolomics reveals that hepatic stearoyl-CoA desaturase 1 downregulation exacerbates inflammation and acute colitis","volume":"7","author":"Chen","year":"2008","journal-title":"Cell Metab"},{"key":"10.1016\/j.plipres.2023.101238_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.plipres.2008.08.001","article-title":"Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)","volume":"48","author":"Musso","year":"2009","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2019.101006","article-title":"ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review","volume":"77","author":"Feng","year":"2020","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb0200","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.molmed.2017.09.001","article-title":"ATP-citrate Lyase in hyperlipidemia and metabolic disorders","volume":"23","author":"Pinkosky","year":"2017","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.plipres.2023.101238_bb0205","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1126\/science.1164097","article-title":"ATP-citrate lyase links cellular metabolism to histone acetylation","volume":"324","author":"Wellen","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.plipres.2023.101238_bb0210","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/cei.12591","article-title":"Citrate modulates lipopolysaccharide-induced monocyte inflammatory responses","volume":"180","author":"Ashbrook","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.plipres.2023.101238_bb0215","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.redox.2014.10.004","article-title":"Mitochondrial dysfunction and tissue injury by alcohol, high fat, nonalcoholic substances and pathological conditions through post-translational protein modifications","volume":"3","author":"Song","year":"2014","journal-title":"Redox Biol"},{"key":"10.1016\/j.plipres.2023.101238_bb0220","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/hep.22774","article-title":"Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice","volume":"49","author":"Wang","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2023.101238_bb0225","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1161\/ATVBAHA.116.308963","article-title":"Prevention of diet-induced metabolic dysregulation, inflammation, and atherosclerosis in Ldlr\u2212\/\u2212 mice by treatment with the ATP-citrate Lyase inhibitor Bempedoic acid","volume":"37","author":"Samsoondar","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.plipres.2023.101238_bb0230","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.cmet.2013.07.004","article-title":"DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery","volume":"18","author":"Ahrens","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.plipres.2023.101238_bb0235","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"CLEAR harmony trial. Safety and efficacy of Bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.plipres.2023.101238_bb0240","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.plipres.2023.101238_bb0245","doi-asserted-by":"crossref","first-page":"E1796","DOI":"10.1073\/pnas.1520686113","article-title":"Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats","volume":"113","author":"Harriman","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.plipres.2023.101238_bb0250","doi-asserted-by":"crossref","first-page":"E187","DOI":"10.1152\/ajpendo.00161.2022","article-title":"Investigating dual inhibition of ACC and CD36 for the treatment of nonalcoholic fatty liver disease in mice","volume":"324","author":"Devereux","year":"2023","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.plipres.2023.101238_bb0255","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jcmgh.2020.06.001","article-title":"Acetyl-CoA carboxylase inhibition improves multiple dimensions of NASH pathogenesis in model systems","volume":"10","author":"Ross","year":"2020","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.plipres.2023.101238_bb0260","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0168-8278(17)30328-8","article-title":"Acetyl-CoA carboxylase (ACC) inhibitor GS-0976 leads to suppression of hepatic de novo lipogenesis and significant improvements in MRI-PDFF, MRE, and markers of fibrosis after 12 weeks of therapy in patients with NASH","volume":"66","author":"Lawitz","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.plipres.2023.101238_bb0265","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0163-7827(02)00067-X","article-title":"Structural and functional organization of the animal fatty acid synthase","volume":"42","author":"Smith","year":"2003","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb0270","doi-asserted-by":"crossref","first-page":"TPS2615","DOI":"10.1200\/jco.2015.33.15_suppl.tps2615","article-title":"First-in-human investigation of the oral first-inclass fatty acid synthase (FASN) inhibitor TVB-2640","volume":"33","author":"Brenner","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.plipres.2023.101238_bb0275","series-title":"TVB-2640. AACR metabolism and cancer conference June 7\u201310, 2015 Bellevue, Washington, USA. Poster CT203","article-title":"Report of a first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor","author":"Patel","year":"2023"},{"key":"10.1016\/j.plipres.2023.101238_bb0280","doi-asserted-by":"crossref","first-page":"15661","DOI":"10.1038\/s41598-022-19459-z","article-title":"FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models","volume":"12","author":"O\u2019Farrell","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.plipres.2023.101238_bb0285","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hep.31000","article-title":"Fatty Acid Synthase Inhibitor TVB-2640 reduces hepatic de novo lipogenesis in males with metabolic abnormalities","volume":"72","author":"Syed-Abdul","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2023.101238_bb0290","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1053\/j.gastro.2021.07.025","article-title":"TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial","volume":"161","author":"Loomba","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.plipres.2023.101238_bb0295","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1194\/jlr.M068197","article-title":"Diacylglycerol acyltransferase 2 links glucose utilization to fatty acid oxidation in the brown adipocytes","volume":"58","author":"Irshad","year":"2017","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb0300","doi-asserted-by":"crossref","first-page":"11767","DOI":"10.1074\/jbc.M311000200","article-title":"Lipopenia and skin barrier abnormalities in DGAT2-deficient mice","volume":"279","author":"Stone","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2023.101238_bb0305","article-title":"Upregulated absorption of dietary saturated fatty acids with changes of intestinal fatty acid transporters in non-alcoholic steatohepatitis","volume":"62","author":"Yamamoto","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2023.101238_bb0310","first-page":"1253","article-title":"Effect of Pradigastat, a diacylglycerol acyltransferase 1 inhibitor, on liver fat content in nonalcoholic fatty liver disease","volume":"62","author":"Sanyal","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2023.101238_bb0315","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1161\/ATVBAHA.114.304584","article-title":"Roles of acyl-CoA: diacylglycerol acyltransferases 1 and 2 in triacylglycerol synthesis and secretion in primary hepatocytes","volume":"35","author":"Li","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.plipres.2023.101238_bb0320","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/labinvest.2012.145","article-title":"Carbon tetrachloride-induced hepatic injury through formation of oxidized diacylglycerol and activation of the PKC\/NF-\u03baB pathway","volume":"93","author":"Toriumi","year":"2013","journal-title":"Lab Invest"},{"key":"10.1016\/j.plipres.2023.101238_bb0325","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1267\/ahc.14030","article-title":"Roles of oxidized diacylglycerol for carbon tetrachloride-induced liver injury and fibrosis in mouse","volume":"47","author":"Takekoshi","year":"2014","journal-title":"Acta Histochem Cytochem"},{"key":"10.1016\/j.plipres.2023.101238_bb0330","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.plipres.2023.101238_bb0335","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1002\/hep.27772","article-title":"Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: all that is gold does not glitter, not all those who wander are lost","volume":"61","author":"Musso","year":"2015","journal-title":"Hepatology."},{"key":"10.1016\/j.plipres.2023.101238_bb0340","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(15)61198-9","article-title":"Trials of obeticholic acid for non-alcoholic steatohepatitis","volume":"386","author":"Musso","year":"2015","journal-title":"Lancet."},{"issue":"Supplement","key":"10.1016\/j.plipres.2023.101238_bb0345","doi-asserted-by":"crossref","first-page":"S546","DOI":"10.14309\/01.ajg.0000593288.44298.be","article-title":"Positive results from REGENERATE: a phase 3 international, randomized, placebo-controlled study evaluating obeticholic acid treatment for NASH","volume":"114","author":"Younossi","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.plipres.2023.101238_bb0350","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.plipres.2010.03.002","article-title":"The liver X receptor: control of cellular lipid homeostasis and beyond implications for drug design","volume":"49","author":"Oosterveer","year":"2010","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb0355","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1152\/ajpendo.00552.2013","article-title":"Sulfation of 25-hydroxycholesterol regulates lipid metabolism, inflammatory responses, and cell proliferation","volume":"306","author":"Ren","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.plipres.2023.101238_bb0360","series-title":"Poster session presented at AASLD\u2019s Emerging Trends in NAFLD","article-title":"DUR-928, an endogenous regulatory molecule, exhibits anti-inflammatory and antifibrotic activity in a mouse model of NASH","author":"Kim","year":"2017"},{"key":"10.1016\/j.plipres.2023.101238_bb0365","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/hep4.1072","article-title":"The selective peroxisome proliferator\u2013activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice","volume":"1","author":"Haczeyni","year":"2017","journal-title":"Hepatol Comm"},{"key":"10.1016\/j.plipres.2023.101238_bb0370","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/hep.26461","article-title":"Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha\/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"58","author":"Staels","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2023.101238_bb0375","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.plipres.2023.101238_bb0380","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1210\/jc.2011-1061","article-title":"MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin","volume":"96","author":"Bays","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.plipres.2023.101238_bb0385","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.4254\/wjh.v14.i7.1365","article-title":"Regulation of PPAR-\u03b3 activity in lipid-laden hepatocytes affects macrophage polarization and inflammation in nonalcoholic fatty liver disease","volume":"14","author":"Li","year":"2022","journal-title":"World J Hepatol"},{"key":"10.1016\/j.plipres.2023.101238_bb0390","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s13105-020-00777-7","article-title":"Regulation of peroxisome proliferator-activated receptor-gamma activity affects the hepatic stellate cell activation and the progression of NASH via TGF-\u03b21\/Smad signaling pathway","volume":"77","author":"Ni","year":"2021","journal-title":"J Physiol Biochem"},{"key":"10.1016\/j.plipres.2023.101238_bb0395","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1517\/14656566.2015.1009894","article-title":"Saroglitazar for the treatment of dyslipidemia in diabetic patients","volume":"16","author":"Joshi","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.plipres.2023.101238_bb0400","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/hep4.1057","article-title":"The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis","volume":"1","author":"Wettstein","year":"2017","journal-title":"Hepatol Comm"},{"key":"10.1016\/j.plipres.2023.101238_bb0405","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2023.101238_bb0410","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.plipres.2023.101238_bb0415","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40265-021-01648-1","article-title":"Chiglitazar: first approval","volume":"82","author":"Deeks","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.plipres.2023.101238_bb0420","doi-asserted-by":"crossref","first-page":"10209","DOI":"10.1073\/pnas.1405158111","article-title":"Poly (ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis","volume":"111","author":"Andrabi","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.plipres.2023.101238_bb0425","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1101\/gad.334516.119","article-title":"PARP and PARG inhibitors in cancer treatment","volume":"34","author":"Slade","year":"2020","journal-title":"Genes Dev"},{"key":"10.1016\/j.plipres.2023.101238_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2021.101117","article-title":"PARPs in lipid metabolism and related diseases","volume":"84","author":"Sz\u00e1nt\u00f3","year":"2021","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb0435","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/dom.14719","article-title":"Positive allosteric \u03b3-aminobutyric acid type a receptor modulation prevents lipotoxicity-induced injury in hepatocytes in vitro","volume":"24","author":"Rohbeck","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.plipres.2023.101238_bb0440","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.cell.2014.03.026","article-title":"Defective mitophagy in XPA via PARP-1 hyperactivation and NAD (+)\/SIRT1 reduction","volume":"157","author":"Fang","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.plipres.2023.101238_bb0445","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/jcp.24907","article-title":"Effect of NAD on PARP-mediated insulin sensitivity in oleic acid treated hepatocytes","volume":"230","author":"Pang","year":"2015","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.plipres.2023.101238_bb0450","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1159\/000354474","article-title":"Relative quantitative comparison between lipotoxicity and glucotoxicity affecting the PARP-NAD-SIRT1 pathway in hepatocytes","volume":"32","author":"Pang","year":"2013","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.plipres.2023.101238_bb0455","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/s41366-020-0573-z","article-title":"Tankyrase inhibition ameliorates lipid disorder via suppression of PGC-1alpha PARylation in db\/db mice","volume":"44","author":"Wang","year":"2020","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.plipres.2023.101238_bb0460","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1124\/jpet.117.243105","article-title":"Poly (ADP-ribose) polymerase inhibitor PJ34 attenuated hepatic triglyceride accumulation in alcoholic fatty liver disease in mice","volume":"364","author":"Huang","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.plipres.2023.101238_bb0465","doi-asserted-by":"crossref","first-page":"10163","DOI":"10.1038\/s41598-017-10824-x","article-title":"Short chain fatty acids enhance aryl hydrocarbon (ah) responsiveness in mouse colonocytes and caco-2 human colon cancer cells","volume":"7","author":"Jin","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.plipres.2023.101238_bb0470","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.3390\/cells11233789","article-title":"Efficacy of clinically used PARP inhibitors in a murine model of acute lung injury","volume":"11","author":"Martins","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.plipres.2023.101238_bb0475","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11239-008-0230-1","volume":"27","author":"Morrow","year":"2009","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.plipres.2023.101238_bb0480","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1016\/j.bbamcr.2013.04.005","article-title":"Poly (ADP-ribose) polymerase-1 -induced NAD depletion promotes nuclear factor-kappa B transcriptional activity by preventing p65 de-acetylation","volume":"1833","author":"Kauppinen","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.plipres.2023.101238_bb0485","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.4049\/jimmunol.1801616","article-title":"C-Abl-mediated tyrosine phosphorylation of PARP1 is crucial for expression of proinflammatory genes","volume":"203","author":"Bohio","year":"2019","journal-title":"J Immunol"},{"key":"10.1016\/j.plipres.2023.101238_bb0490","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.4049\/jimmunol.1400359","article-title":"PARP-1 mediates LPS-induced HMGB1 release by macrophages through regulation of HMGB1 acetylation","volume":"193","author":"Yang","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.plipres.2023.101238_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2020.153021","article-title":"PARP-1 inhibitor-AG14361 suppresses acute allograft rejection via stabilizing CD4+FoxP3+ regulatory T cells","volume":"216","author":"Gu","year":"2020","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.plipres.2023.101238_bb0500","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.4049\/jimmunol.0901568","article-title":"Increased Foxp3+ regulatory T cells in poly (ADP-ribose) polymerase-1 deficiency","volume":"184","author":"Nasta","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.plipres.2023.101238_bb0505","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1101\/gad.334284.119","article-title":"The role of ADP-ribose metabolism in metabolic regulation, adipose tissue differentiation, and metabolism","volume":"34","author":"Sz\u00e1nt\u00f3","year":"2020","journal-title":"Genes Dev"},{"key":"10.1016\/j.plipres.2023.101238_bb0510","first-page":"30250","article-title":"Olaparib induces browning of in vitro cultures of human primary white adipocytes","volume":"25","author":"Nagy","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.plipres.2023.101238_bb0515","doi-asserted-by":"crossref","first-page":"37738","DOI":"10.1074\/jbc.M701021200","article-title":"Poly (ADPribose) polymerase-2 controls adipocyte differentiation and adipose tissue function through the regulation of the activity of the retinoid X receptor\/peroxisome proliferator-activated receptor-gamma heterodimer","volume":"282","author":"Bai","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2023.101238_bb0520","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1096\/fj.11-200212","article-title":"ARTD1 deletion causes increased hepatic lipid accumulation in mice fed a high fat diet and impairs adipocyte function and differentiation","volume":"26","author":"Erener","year":"2012","journal-title":"FASEB J"},{"key":"10.1016\/j.plipres.2023.101238_bb0525","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1002\/hep.30652","article-title":"Fructose promotes leaky gut, endotoxemia, and liver fibrosis through ethanol-inducible cytochrome P450-2E1-mediated oxidative and nitrative stress","volume":"73","author":"Cho","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2023.101238_bb0530","first-page":"4335","article-title":"Deletion of poly (ADP ribose) polymerase-1 changes the composition of the microbiome in the gut","volume":"18","author":"Vida","year":"2018","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.plipres.2023.101238_bb0535","doi-asserted-by":"crossref","first-page":"8918","DOI":"10.1074\/jbc.M116.714386","article-title":"Transcriptional reprogramming and resistance to colonic mucosal injury in poly (ADP-ribose) polymerase 1 (PARP1)-deficient mice","volume":"291","author":"Larmonier","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2023.101238_bb0540","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jhep.2016.08.024","article-title":"Inhibiting poly ADP ribosylation increases fatty acid oxidation and protects against fatty liver disease","volume":"66","author":"Gariani","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.plipres.2023.101238_bb0545","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1002\/ptr.6417","article-title":"Puerarin protects against high-fat high-sucrose diet-induced non-alcoholic fatty liver disease by modulating PARP-1\/PI3K\/AKT signaling pathway and facilitating mitochondrial homeostasis","volume":"33","author":"Wang","year":"2019","journal-title":"Phytother Res"},{"key":"10.1016\/j.plipres.2023.101238_bb0550","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jhep.2016.11.020","article-title":"PARP1-mediated PPAR\u03b1 poly ADP-ribosylation suppresses fatty acid oxidation in non-alcoholic fatty liver disease","volume":"66","author":"Huang","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.plipres.2023.101238_bb0555","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.10.023","article-title":"PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis","volume":"66","author":"Mukhopadhyay","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.plipres.2023.101238_bb0560","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.fct.2017.02.039","article-title":"Diet high in fructose promotes liver steatosis and hepatocyte apoptosis in C57BL\/6J female mice: role of disturbed lipid homeostasis and increased oxidative stress","volume":"103","author":"Choi","year":"2017","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.plipres.2023.101238_bb0565","first-page":"287","article-title":"Liver disease and dyslipidemia as a manifestation of lysosomal acid lipase deficiency (LAL-D). Clinical and diagnostic aspects, and a new treatment. An update","volume":"115","author":"Bay","year":"2017","journal-title":"Arch Argent Pediatr"},{"key":"10.1016\/j.plipres.2023.101238_bb0570","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.jhep.2013.02.014","article-title":"Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease","volume":"58","author":"Bernstein","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.plipres.2023.101238_bb0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2021.101109","article-title":"Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis","volume":"83","author":"Li","year":"2021","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb0580","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.cgh.2021.07.016","article-title":"Natural history of nonalcoholic fatty liver disease with normal body mass index: a population-based study","volume":"20","author":"Ahmed","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.plipres.2023.101238_bb0585","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2023.101238_bb0590","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.820","article-title":"Effect of a common missense variant in LIPA gene on fatty liver disease and lipid phenotype: new perspectives from a single-center observational study","volume":"9","author":"Pasta","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.plipres.2023.101238_bb0595","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3390\/ijms17030312","article-title":"Low serum lysosomal acid lipase activity correlates with advanced liver disease","volume":"17","author":"Sheteyer","year":"2016","journal-title":"Int J Mol"},{"key":"10.1016\/j.plipres.2023.101238_bb0600","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.dld.2016.04.014","article-title":"Reduced lysosomal acid lipase activity - a potential role in the pathogenesis of non alcoholic fatty liver disease in pediatric patients","volume":"48","author":"Selvakumar","year":"2016","journal-title":"Dig Liver Dis Dig"},{"key":"10.1016\/j.plipres.2023.101238_bb0605","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.3390\/ijms18061134","article-title":"A relative deficiency of lysosomal acid lypase activity characterizes non-alcoholic fatty liver disease","volume":"18","author":"Tovoli","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.plipres.2023.101238_bb0610","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.atherosclerosis.2017.03.038","article-title":"Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study","volume":"262","author":"Angelico","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.plipres.2023.101238_bb0615","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/gim.2015.108","article-title":"Rapid progression and mortality of lysosomal acid lipase deficiency presenting in infants","volume":"18","author":"Jones","year":"2016","journal-title":"Genet Med"},{"key":"10.1016\/j.plipres.2023.101238_bb0620","doi-asserted-by":"crossref","DOI":"10.1080\/03007995.2017.1309371","article-title":"Progression of liver disease in children and adults with lysosomal acid lipase deficiency","author":"Burton","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.plipres.2023.101238_bb0625","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/ATVBAHA.116.308734","article-title":"Coronary artery disease-associated LIPA coding variant rs1051338 reduces lysosomal acid lipase levels and activity in lysosomes","volume":"37","author":"Morris","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.plipres.2023.101238_bb0630","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.jceh.2022.04.011","article-title":"Lysosomal acid lipase activity in non-alcoholic fatty liver disease as a novel diagnostic and therapeutic target: a systematic literature review of current evidence and future directions","volume":"12","author":"Bashir","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.plipres.2023.101238_bb0635","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/j.ymgme.2013.12.215","article-title":"Sustained elevations in LDL cholesterol and serum transaminases from early childhood are common in lysosomal acid lipase deficiency","volume":"111","author":"Quinn","year":"2014","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.plipres.2023.101238_bb0640","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-0214","article-title":"Lysosomal acid lipase deficiency unmasked in two children with nonalcoholic fatty liver disease","volume":"138","author":"Himes","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.plipres.2023.101238_bb0645","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jhep.2013.04.016","article-title":"Hepatic cholesteryl ester accumulation in lysosomal acid lipase deficiency: non-invasive identification and treatment monitoring by magnetic resonance","volume":"59","author":"Thelwall","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.plipres.2023.101238_bb0650","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/j.1365-2559.2011.04164.x","article-title":"Distinctive histopathological features that support a diagnosis of cholesterol ester storage disease in liver biopsy specimens","volume":"60","author":"Hulkova","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.plipres.2023.101238_bb0655","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.cca.2012.03.019","article-title":"A new method for the measurement of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2","volume":"413","author":"Hamilton","year":"2012","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.plipres.2023.101238_bb0660","series-title":"Endotext [internet]","article-title":"Lysosomal acid lipase deficiency","author":"Desai","year":"2000"},{"key":"10.1016\/j.plipres.2023.101238_bb0665","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/hep.26327","article-title":"Frequency of the cholesteryl ester storage disease common LIPA E8SJM mutation (c.894G>A) in various racial and ethnic groups","volume":"58","author":"Scott","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2023.101238_bb0670","first-page":"279A","article-title":"Change in liver fibrosis in children and adults with lysosomal acid lipase deficiency after 52 weeks of Sebelipase alfa (ARISE trial)","volume":"64","author":"Goodman","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2023.101238_bb0675","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1053\/j.gastro.2022.06.023","article-title":"AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review","volume":"163","author":"Long","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.plipres.2023.101238_bb0680","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1007\/s00125-019-05014-5","article-title":"Extracellular vesicles in metabolic disease","volume":"62","author":"Akbar","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.plipres.2023.101238_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.117094","article-title":"Extracellular vesicles participate in macrophage-involved immune responses under liver diseases","volume":"240","author":"Shao","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.plipres.2023.101238_bb0690","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.trecan.2016.05.007","article-title":"Tumor-stromal cell communication: small vesicles signal big changes","volume":"2","author":"Wendler","year":"2016","journal-title":"Trends Cancer"},{"key":"10.1016\/j.plipres.2023.101238_bb0695","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1053\/j.gastro.2012.04.031","article-title":"Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis","volume":"143","author":"Kornek","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.plipres.2023.101238_bb0700","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1194\/jlr.M063412","article-title":"Hepatocytes release ceramide-enriched proinflammatory extracellular vesicles in an IRE1\u03b1-dependent manner","volume":"57","author":"Kakazu","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb0705","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/hep4.1404","article-title":"Characterization of cellular sources and circulating levels of extracellular vesicles in a dietary murine model of nonalcoholic steatohepatitis","volume":"3","author":"Li","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.plipres.2023.101238_bb0710","doi-asserted-by":"crossref","first-page":"15277","DOI":"10.1074\/jbc.RA118.002587","article-title":"StAR-related lipid transfer domain 11 (STARD11)-mediated ceramide transport mediates extracellular vesicle biogenesis","volume":"293","author":"Fukushima","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2023.101238_bb0715","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.735001","article-title":"A comparative proteomic analysis of extracellular vesicles associated with lipotoxicity","volume":"9","author":"Nakao","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.plipres.2023.101238_bb0720","doi-asserted-by":"crossref","first-page":"ra88","DOI":"10.1126\/scisignal.2004512","article-title":"Lipid-induced toxicity stimulates hepatocytes to release angiogenic microparticles that require Vanin-1 for uptake by endothelial cells","volume":"6","author":"Povero","year":"2013","journal-title":"Sci Signal"},{"key":"10.1016\/j.plipres.2023.101238_bb0725","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jcmgh.2015.07.007","article-title":"Lipid-induced hepatocyte-derived extracellular vesicles regulate hepatic stellate cell via micro RNAs targeting PPAR-\u03b3","volume":"1","author":"Povero","year":"2015","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.plipres.2023.101238_bb0730","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/hep.28252","article-title":"Mixed lineage kinase 3 mediates release of C-X-C motif ligand 10-bearing chemotactic extracellular vesicles from lipotoxic hepatocytes","volume":"63","author":"Ibrahim","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2023.101238_bb0735","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1002\/jcb.25973","article-title":"Mixed lineage kinase 3 mediates the induction of CXCL10 by a STAT1-dependent mechanism during hepatocyte lipotoxicity","volume":"118","author":"Tomita","year":"2017","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.plipres.2023.101238_bb0740","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1053\/j.gastro.2015.12.037","article-title":"Lipid-induced signaling causes release of inflammatory extracellular vesicles from hepatocytes","volume":"150","author":"Hirsova","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.plipres.2023.101238_bb0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2019.111738","article-title":"Cholesterol impairs hepatocyte lysosomal function causing M1 polarization of macrophages via exosomal miR-122-5p","volume":"387","author":"Zhao","year":"2020","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.plipres.2023.101238_bb0750","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1194\/jlr.M063412","article-title":"Hepatocytes release ceramide-enriched pro-inflammatory extracellular vesicles in an IRE1alpha-dependent manner","volume":"57","author":"Kakazu","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb0755","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.3389\/fimmu.2018.02980","article-title":"Hepatocyte-derived lipotoxic extracellular vesicle sphingosine 1-phosphate induces macrophage chemotaxis","volume":"9","author":"Liao","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.plipres.2023.101238_bb0760","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1172\/JCI83885","article-title":"Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9","volume":"126","author":"Garcia-Martinez","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.plipres.2023.101238_bb0765","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/hep.23999","article-title":"Human T cell microparticles circulate in blood of hepatitis patients and induce fibrolytic activation of hepatic stellate cells","volume":"53","author":"Kornek","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2023.101238_bb0770","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1053\/j.gastro.2008.09.066","article-title":"Liver cell-derived microparticles activate hedgehog signaling and alter gene expression in hepatic endothelial cells","volume":"136","author":"Witek","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.plipres.2023.101238_bb0775","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/hep.27318","article-title":"Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles","volume":"61","author":"Lemoinne","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2023.101238_bb0780","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.surg.2014.04.014","article-title":"Exosomes mediate intercellular transfer of pro-fibrogenic connective tissue growth factor (CCN2) between hepatic stellate cells, the principal fibrotic cells in the liver","volume":"156","author":"Charrier","year":"2014","journal-title":"Surgery"},{"key":"10.1016\/j.plipres.2023.101238_bb0785","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00109-016-1446-8","article-title":"Circulating adipocyte-derived extracellular vesicles are novel markers of metabolic stress","volume":"94","author":"Eguchi","year":"2016","journal-title":"J Mol Med"},{"key":"10.1016\/j.plipres.2023.101238_bb0790","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12876-014-0208-8","article-title":"Expression of NALPs in adipose and the fibrotic progression of non-alcoholic fatty liver disease in obese subjects","volume":"14","author":"Mehta","year":"2014","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.plipres.2023.101238_bb0795","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/jmcb\/mjw040","article-title":"Adipocyte-derived microvesicles from obese mice induce M1 macrophage phenotype through secreted miR-155","volume":"8","author":"Zhang","year":"2016","journal-title":"J Mol Cell Biol"},{"key":"10.1016\/j.plipres.2023.101238_bb0800","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1172\/JCI123069","article-title":"Adipocyte-secreted exosomal microRNA-34a inhibits M2 macrophage polarization to promote obesity-induced adipose inflammation","volume":"129","author":"Pan","year":"2019","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.plipres.2023.101238_bb0805","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s13167-017-0117-3","article-title":"Comparative study of probiotic effects of Lactobacillus and Bifidobacteria strains on cholesterol levels, liver morphology and the gut microbiota in obese mice","volume":"8","author":"Bubnov","year":"2017","journal-title":"EPMA J"},{"key":"10.1016\/j.plipres.2023.101238_bb0810","doi-asserted-by":"crossref","first-page":"26238","DOI":"10.3402\/jev.v4.26238","article-title":"Macrophage-dependent clearance of systemically administered B16BL6-derived exosomes from the blood circulation in mice","volume":"4","author":"Takafumi","year":"2015","journal-title":"J Extracell Vesicles"},{"key":"10.1016\/j.plipres.2023.101238_bb0815","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.nano.2014.03.014","article-title":"Exosome-mediated delivery of functionally active miRNA-155 inhibitor to macrophages","volume":"10","author":"Momen-Heravi","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.plipres.2023.101238_bb0820","doi-asserted-by":"crossref","first-page":"8182","DOI":"10.1002\/jcp.27615","article-title":"Therapeutic use of curcumin-encapsulated and curcumin-primed exosomes","volume":"234","author":"Oskouie","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.plipres.2023.101238_bb0825","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13287-019-1539-8","article-title":"hUCMSC-extracellular vesicles downregulated hepatic stellate cell activation and reduced liver injury in S. japonicum-infected mice","volume":"11","author":"Dong","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.plipres.2023.101238_bb0830","article-title":"Human induced pluripotent stem cell-derived extracellular vesicles reduce hepatic stellate cell activation and liver fibrosis","volume":"5","author":"Povero","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.plipres.2023.101238_bb0835","doi-asserted-by":"crossref","first-page":"G77","DOI":"10.1152\/ajpgi.00301.2011","article-title":"Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis","volume":"302","author":"Kakisaka","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.plipres.2023.101238_bb0840","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.bbalip.2013.11.013","article-title":"Micromolar changes in lysophosphatidylcholine concentration cause minor effects on mitochondrial permeability but major alterations in function","volume":"1841","author":"Hollie","year":"2014","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10.1016\/j.plipres.2023.101238_bb0845","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1878-5085-5-21","article-title":"4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics","volume":"5","author":"Trovato","year":"2014","journal-title":"EPMA J"},{"issue":"1","key":"10.1016\/j.plipres.2023.101238_bb0850","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s13167-017-0115-5","article-title":"High regenerative capacity of the liver and irreversible injury of male reproductive system in carbon tetrachloride-induced liver fibrosis rat model","volume":"9","author":"Bubnov","year":"2017","journal-title":"EPMA J"},{"key":"10.1016\/j.plipres.2023.101238_bb0855","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/hep.28973","article-title":"Hepatocyte autotaxin expression promotes liver fibrosis and cancer","volume":"65","author":"Kaffe","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2023.101238_bb0860","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cmet.2006.03.007","article-title":"The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis","volume":"3","author":"Li","year":"2006","journal-title":"Cell Metab"},{"key":"10.1016\/j.plipres.2023.101238_bb0865","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.cell.2011.09.045","article-title":"A conserved SREBP-1\/phosphatidylcholine feedback circuit regulates lipogenesis in metazoans","volume":"147","author":"Walker","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.plipres.2023.101238_bb0870","doi-asserted-by":"crossref","first-page":"8901","DOI":"10.1073\/pnas.1408523111","article-title":"Mutations disrupting the Kennedy-phosphatidylcholine pathway in humans with congenital lipodystrophy and fatty liver disease","volume":"111","author":"Payne","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.plipres.2023.101238_bb0875","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1124\/jpet.115.229906","article-title":"ASB14780, an orally active inhibitor of group IVA phospholipase A2, is a Pharmacotherapeutic candidate for nonalcoholic fatty liver disease","volume":"356","author":"Kanai","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.plipres.2023.101238_bb0880","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.plipres.2017.01.002","article-title":"Sphingolipids and glycerophospholipids - The \u201cying and yang\u201d of lipotoxicity in metabolic diseases","volume":"66","author":"Rodriguez-Cuenca","year":"2017","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb0885","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3389\/fphys.2014.00331","article-title":"Inhibition of acid sphingomyelinase by tricyclic antidepressants and analogous","volume":"5","author":"Beckmann","year":"2014","journal-title":"Front Physiol"},{"key":"10.1016\/j.plipres.2023.101238_bb0890","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1038\/ncomms10166","article-title":"Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction","volume":"6","author":"Jiang","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.plipres.2023.101238_bb0895","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1172\/JCI43378","article-title":"Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice","volume":"121","author":"Holland","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.plipres.2023.101238_bb0900","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.cmet.2014.09.015","article-title":"CerS2 haploinsufficiency inhibits b-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance","volume":"20","author":"Raichur","year":"2014","journal-title":"Cell Metab"},{"key":"10.1016\/j.plipres.2023.101238_bb0905","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.cmet.2014.08.002","article-title":"Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance","volume":"20","author":"Turpin","year":"2014","journal-title":"Cell Metab"},{"key":"10.1016\/j.plipres.2023.101238_bb0910","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/2045-3701-4-71","article-title":"Induction of ER stress-mediated apoptosis by ceramide via disruption of ERCa (2+) homeostasis in human adenoid cystic carcinoma cells","volume":"4","author":"Liu","year":"2014","journal-title":"Cell Biosci"},{"key":"10.1016\/j.plipres.2023.101238_bb0915","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/hep.26606","article-title":"Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides","volume":"59","author":"Cinar","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2023.101238_bb0920","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jhep.2014.06.009","article-title":"ASMase regulates autophagy and lysosomal membrane permeabilization and its inhibition prevents early stage non-alcoholic steatohepatitis","volume":"60","author":"Fucho","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.plipres.2023.101238_bb0925","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s10495-015-1108-2","article-title":"Autophagy in the light of sphingolipid metabolism","volume":"20","author":"Harvald","year":"2015","journal-title":"Apoptosis"},{"key":"10.1016\/j.plipres.2023.101238_bb0930","article-title":"Ceramide induces human hepcidin gene transcription through JAK\/STAT3 pathway","volume":"11","author":"Lu","year":"2016","journal-title":"PLoSOne"},{"key":"10.1016\/j.plipres.2023.101238_bb0935","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.2353\/ajpath.2010.091257","article-title":"Acidic sphingomyelinase controls hepatic stellate cell activation and in vivo liver fibrogenesis","volume":"177","author":"Moles","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.plipres.2023.101238_bb0940","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.chemphyslip.2015.07.008","article-title":"Inhibitors of the sphingomyelin cycle: sphingomyelin synthases and sphingomyelinases","volume":"197","author":"Adada","year":"2016","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/j.plipres.2023.101238_bb0945","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.2337\/db09-1293","article-title":"Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption","volume":"59","author":"Ussher","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.plipres.2023.101238_bb0950","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126910","article-title":"Ceramide as a mediator of non-alcoholic fatty liver disease and associated atherosclerosis","volume":"10","author":"Kasumov","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.plipres.2023.101238_bb0955","doi-asserted-by":"crossref","first-page":"12962","DOI":"10.1073\/pnas.1516733112","article-title":"Elevation of 20-carbon long chain bases due to a mutation in serine palmitoyl transferase small subunit b results in neurodegeneration","volume":"112","author":"Zhao","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.plipres.2023.101238_bb0960","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.plipres.2016.03.006","article-title":"The enigma of ceramide synthase regulation in mammalian cells","volume":"63","author":"Wegner","year":"2016","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb0965","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.biochi.2011.09.007","article-title":"Inhibitors of specific ceramide synthases","volume":"94","author":"Schiffmann","year":"2012","journal-title":"Biochimie"},{"key":"10.1016\/j.plipres.2023.101238_bb0970","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1074\/jbc.M115.668228","article-title":"SIRT3 deacetylates ceramide synthases: implications for mitochondrial dysfunction and brain injury","volume":"291","author":"Novgorodov","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2023.101238_bb0975","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00109-017-1564-y","article-title":"Fenretinide differentially modulates the levels of long- and very long-chain ceramides by downregulating Cers5 enzyme: evidence from bench to bedside","volume":"95","author":"Gari\u0107","year":"2017","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.plipres.2023.101238_bb0980","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bcp.2015.11.017","article-title":"Fenretinide mediated retinoic acid receptor signalling and inhibition of ceramide biosynthesis regulates adipogenesis, lipid accumulation, mitochondrial function and nutrient stress signalling in adipocytes and adipose tissue","volume":"100","author":"Mcilroy","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.plipres.2023.101238_bb0985","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1042\/BJ20141455","article-title":"Metabolomic profiling in liver of adiponectin knockout mice uncovers lysophospholipid metabolism as an important target of adiponectin action","volume":"469","author":"Liu","year":"2015","journal-title":"Biochem J"},{"key":"10.1016\/j.plipres.2023.101238_bb0990","series-title":"American Diabetes Association 75th scientific sessions","article-title":"Targeted induction of ceramide degradation reveals roles for ceramides in nonalcoholic fatty liver disease and glucose metabolism","author":"Xia","year":"2015"},{"key":"10.1016\/j.plipres.2023.101238_bb0995","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3390\/ijms19030722","article-title":"Divergent role of sphingosine 1-phosphate in liver health and disease","volume":"19","author":"Kleuser","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.plipres.2023.101238_bb1000","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/nature09128","article-title":"Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2","volume":"465","author":"Alvarez","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.plipres.2023.101238_bb1005","doi-asserted-by":"crossref","first-page":"37118","DOI":"10.1074\/jbc.M502207200","article-title":"SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism","volume":"280","author":"Maceyka","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2023.101238_bb1010","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1194\/jlr.M063511","article-title":"SphK1 mediates hepatic inflammation in a mouse model of NASH induced by high saturated fat feeding and initiates proinflammatory signaling in hepatocytes","volume":"56","author":"Geng","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb1015","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.jhep.2010.08.028","article-title":"Sphingosine 1-phosphate (S1P)\/S1P receptors are involved in human liver fibrosis by action on hepatic myofibroblasts motility","volume":"54","author":"Li","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.plipres.2023.101238_bb1020","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1096\/fj.13-230052","article-title":"Loss of sphingosine kinase 1 predisposes to the onset of diabetes via promoting pancreatic beta-cell death in diet-induced obese mice","volume":"27","author":"Qi","year":"2013","journal-title":"FASEB J"},{"key":"10.1016\/j.plipres.2023.101238_bb1025","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.bbalip.2014.12.002","article-title":"Overexpression of sphingosine kinase 1 in liver reduces triglyceride content in mice fed a low but not high-fat diet","volume":"1851","author":"Kowalski","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.plipres.2023.101238_bb1030","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/hep.27804","article-title":"Activation of sphingosine kinase 2 by endoplasmic reticulum stress ameliorates hepatic steatosis and insulin-resistance in mice","volume":"62","author":"Lee","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2023.101238_bb1035","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1194\/jlr.M010595","article-title":"Circulating sphingolipid biomarkers in models of type 1 diabetes","volume":"52","author":"Fox","year":"2011","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb1040","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00125-013-3123-6","article-title":"Involvement of sphingosine 1-phosphate in palmitate-induced insulin resistance of hepatocytes via the S1P2 receptor subtype","volume":"57","author":"Fayyaz","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.plipres.2023.101238_bb1045","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.molmet.2017.01.002","article-title":"Inducible overexpression of adiponectin receptors highlight the roles of adiponectin-induced ceramidase signaling in lipid and glucose homeostasis","volume":"6","author":"Holland","year":"2017","journal-title":"Mol Metab"},{"key":"10.1016\/j.plipres.2023.101238_bb1050","first-page":"271","article-title":"A lipidomic readout of disease progression in a diet-induced mouse model of nonalcoholic fatty liver disease","volume":"126","author":"Sanyal","year":"2015","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"10.1016\/j.plipres.2023.101238_bb1055","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.bcp.2013.10.005","article-title":"Morin reduces hepatic inflammation-associated lipid accumulation in high fructose-fed rats via inhibiting sphingosine kinase 1\/sphingosine 1-phosphate signaling pathway","volume":"86","author":"Wang","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.plipres.2023.101238_bb1060","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.bbalip.2015.11.006","article-title":"Deletion of sphingosine kinase 1 ameliorates hepatic steatosis in diet-induced obese mice: role of PPAR\u03b3","volume":"1861","author":"Chen","year":"2016","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10.1016\/j.plipres.2023.101238_bb1065","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s13167-020-00198-y","article-title":"Effect of probiotics on obesity-related markers per enterotype: a double-blind, placebo-controlled, randomized clinical trial","volume":"11","author":"Song","year":"2020","journal-title":"EPMA J"},{"key":"10.1016\/j.plipres.2023.101238_bb1070","doi-asserted-by":"crossref","first-page":"E756","DOI":"10.1152\/ajpendo.00549.2013","article-title":"Sphingosine kinase 1 regulates adipose proinflammatory responses and insulin resistance","volume":"306","author":"Wang","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.plipres.2023.101238_bb1075","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/hep.27592","article-title":"Conjugated bile acid-activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression","volume":"61","author":"Nagahashi","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2023.101238_bb1080","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/biof.1342","article-title":"Inhibition of the SPHK1\/S1P signaling pathway by melatonin in mice with liver fibrosis and human hepatic stellate cells","volume":"43","author":"Gonzalez-Fernandez","year":"2017","journal-title":"Biofactors"},{"key":"10.1016\/j.plipres.2023.101238_bb1085","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jhep.2013.02.021","article-title":"Sphingosine kinase\/sphingosine 1-phosphate (S1P)\/S1P receptor axis is involved in liver fibrosis-associated angiogenesis","volume":"59","author":"Yang","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.plipres.2023.101238_bb1090","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ajpath.2014.09.023","article-title":"Intracellular sphingosine 1-phosphate contributes to collagen expression of hepatic myofibroblasts in human liver fibrosis independent of its receptors","volume":"185","author":"Xiu","year":"2015","journal-title":"Am J Pathol"},{"key":"10.1016\/j.plipres.2023.101238_bb1095","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1194\/jlr.M800496-JLR200","article-title":"Sphingosine 1-phosphate regulates regeneration and fibrosis after liver injury via sphingosine 1-phosphate receptor 2","volume":"50","author":"Ikeda","year":"2009","journal-title":"J Lipid Res"},{"issue":"4","key":"10.1016\/j.plipres.2023.101238_bb1100","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s13167-017-0106-6","article-title":"PCSK9 signaling pathways and their potential importance in clinical practice","volume":"8","author":"Wici\u0144ski","year":"2017","journal-title":"EPMA J"},{"issue":"2","key":"10.1016\/j.plipres.2023.101238_bb1105","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s13167-022-00280-7","article-title":"Methods to evaluate vascular function: a crucial approach towards predictive, preventive, and personalised medicine","volume":"13","author":"Sena","year":"2022","journal-title":"EPMA J"},{"key":"10.1016\/j.plipres.2023.101238_bb1110","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.jhep.2009.01.028","article-title":"Homing of bone marrow mesenchymal stem cells mediated by sphingosine 1-phosphate contributes to liver fibrosis","volume":"50","author":"Li","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.plipres.2023.101238_bb1115","doi-asserted-by":"crossref","first-page":"G300","DOI":"10.1152\/ajpgi.00222.2016","article-title":"Inhibition of sphingosine 1-phosphate signaling ameliorates murine nonalcoholic steatohepatitis","volume":"312","author":"Mauer","year":"2017","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.plipres.2023.101238_bb1120","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1159\/000453213","article-title":"Involvement of sphingosine 1-phosphate in palmitate-induced non-alcoholic fatty liver disease","volume":"40","author":"Fadel","year":"2016","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.plipres.2023.101238_bb1125","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis","volume":"9","author":"Brinkmann","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.plipres.2023.101238_bb1130","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.87058","article-title":"HDL activation of endothelial sphingosine-1-phosphate receptor-1 (S1P1) promotes regeneration and suppresses fibrosis in the liver","volume":"1","author":"Ding","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.plipres.2023.101238_bb1135","series-title":"Adipocyte-specific deficiency of de novo sphingolipid biosynthesis leads to lipodystrophy and insulin resistance","first-page":"2596","volume":"66","author":"Lee","year":"2017"},{"key":"10.1016\/j.plipres.2023.101238_bb1140","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10549-017-4380-8","article-title":"New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumor growth","volume":"165","author":"Alshaker","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.plipres.2023.101238_bb1145","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.plipres.2010.05.003","article-title":"Biosynthesis and bioavailability of long-chain polyunsaturated fatty acids in non-alcoholic fatty liver disease","volume":"49","author":"Gormaz","year":"2010","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb1150","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3109\/10408363.2015.1092106","article-title":"Omega-3 fatty acids: mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD","volume":"53","author":"Nobili","year":"2016","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.plipres.2023.101238_bb1155","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.plefa.2005.01.002","article-title":"A defect in the activity of Delta6 and Delta5 desaturases may be a factor predisposing to the development of insulin resistance syndrome","volume":"72","author":"Das","year":"2005","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.plipres.2023.101238_bb1160","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.3748\/wjg.v22.i8.2533","article-title":"Dietary saturated fatty acid and polyunsaturated fatty acid oppositely affect hepatic NOD-like receptor protein 3 inflammasome through regulating nuclear factor-kappa B activation","volume":"22","author":"Sui","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.plipres.2023.101238_bb1165","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2022.101157","article-title":"Desaturases and elongases involved in long-chain polyunsaturated fatty acid biosynthesis in aquatic animals: from genes to functions","volume":"86","author":"Monroig","year":"2022","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb1170","article-title":"Enzymatically-epoxidized docosahexaenoic acid, 19,20-EpDPE, suppresses hepatic crown-like structure formation and nonalcoholic steatohepatitis fibrosis through GPR120","volume":"1868","author":"Aoki","year":"2023","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"10.1016\/j.plipres.2023.101238_bb1175","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1194\/jlr.M061275","article-title":"Docosahexaenoic acid attenuates Western diet-induced hepatic fibrosis in Ldlr\u2212\/\u2212 mice by targeting the TGF\u03b2-Smad3 pathway","volume":"56","author":"Lytle","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb1180","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.3390\/ijms22115675","article-title":"DHA protects hepatocytes from oxidative injury through GPR120\/ERK-mediated Mitophagy","volume":"22","author":"Chen","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.plipres.2023.101238_bb1185","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1248\/yakushi.19-00011-4","article-title":"Involvement of the free fatty acid receptor GPR120\/FFAR4 in the development of nonalcoholic steatohepatitis","volume":"139","author":"Nakamoto","year":"2019","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.plipres.2023.101238_bb1190","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2020.101047","article-title":"Molecular mechanisms for biosynthesis and assembly of nutritionally important very long chain polyunsaturated fatty acids in microorganisms","volume":"79","author":"Qiu","year":"2020","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb1195","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.metabol.2016.01.011","article-title":"Fatty acid metabolism is altered in non-alcoholic steatohepatitis independent of obesity","volume":"65","author":"Walle","year":"2016","journal-title":"Metabolism."},{"key":"10.1016\/j.plipres.2023.101238_bb1200","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1161\/ATVBAHA.117.309660","article-title":"\u0394-5 fatty acid desaturase FADS1 impacts metabolic disease by balancing proinflammatory and proresolving lipid mediators","volume":"38","author":"Gromovsky","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.plipres.2023.101238_bb1205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166198","article-title":"A novel selective inhibitor of Delta-5 desaturase lowers insulin resistance and reduces body weight in diet-induced obese C57BL\/6J mice","volume":"11","author":"Yashiro","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.plipres.2023.101238_bb1210","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/hep.27373","article-title":"Fatty acid desaturase 1 gene polymorphisms control human hepatic lipid composition","volume":"61","author":"Wang","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2023.101238_bb1215","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1080\/00365510601175463","article-title":"Regulation of desaturase expression in HL60 cells","volume":"67","author":"Slagsvold","year":"2007","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.plipres.2023.101238_bb1220","doi-asserted-by":"crossref","first-page":"37335","DOI":"10.1074\/jbc.274.52.37335","article-title":"Cloning, expression, and fatty acid regulation of the human delta-5 desaturase","volume":"274","author":"Cho","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2023.101238_bb1225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162368","article-title":"Effectiveness of omega-3 polyunsaturated fatty acids in non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"11","author":"He","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.plipres.2023.101238_bb1230","doi-asserted-by":"crossref","first-page":"718","DOI":"10.4049\/jimmunol.1601543","article-title":"Neutrophil Resolvin E1 receptor expression and function in type 2 diabetes","volume":"198","author":"Freire","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.plipres.2023.101238_bb1235","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J Basic Clin Pharm"},{"key":"10.1016\/j.plipres.2023.101238_bb1240","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.plipres.2014.07.001","article-title":"Metabolic engineering of microorganisms to produce omega-3 very long-chain polyunsaturated fatty acids","volume":"56","author":"Gong","year":"2014","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb1245","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1194\/jlr.RA119000200","article-title":"Decreased \u03c9-6:\u03c9-3 PUFA ratio attenuates ethanol-induced alterations in intestinal homeostasis, microbiota, and liver injury","volume":"60","author":"Warner","year":"2019","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb1250","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1080\/13543784.2022.2159804","article-title":"Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH","volume":"31","author":"Fraser","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.plipres.2023.101238_bb1255","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2021.12.004","article-title":"A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH","volume":"76","author":"Fraser","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.plipres.2023.101238_bb1260","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1111\/liv.14643","article-title":"Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative","volume":"40","author":"Stokman","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.plipres.2023.101238_bb1265","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/hep4.1453","article-title":"Icosabutate exerts beneficial effects upon insulin sensitivity, hepatic inflammation, lipotoxicity, and fibrosis in mice","volume":"4","author":"Van den Hoek","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.plipres.2023.101238_bb1270","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2020.08.001","article-title":"Epoxygenase-derived epoxyeicosatrienoic acid mediators are associated with nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and fibrosis","volume":"159","author":"Arvind","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.plipres.2023.101238_bb1275","article-title":"Icosabutate, a novel structurally engineered fatty acid, significantly reduces relevant markers of NASH and fibrosis in 16 weeks: interim analysis results of the ICONA trial","volume":"75","author":"Gn","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.plipres.2023.101238_bb1280","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1053\/j.gastro.2018.06.031","article-title":"Bioactive lipid species and metabolic pathways in progression and resolution of nonalcoholic steatohepatitis","volume":"155","author":"Musso","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.plipres.2023.101238_bb1285","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/hep.25739","article-title":"Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism","volume":"56","author":"Musso","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2023.101238_bb1290","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/thoraxjnl-2015-206782","article-title":"Altered gut-liver axis and hepatic adiponectin expression in OSAS: novel mediators of liver injury in paediatric non-alcoholic fatty liver","volume":"70","author":"Nobili","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.plipres.2023.101238_bb1295","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1089\/ars.2017.7332","article-title":"The eicosanoids, redox-regulated lipid mediators in immuno metabolic disorders","volume":"29","author":"Ara\u00fajo","year":"2018","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.plipres.2023.101238_bb1300","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1042\/EBC20190082","volume":"64","author":"Christie","year":"2020","journal-title":"Essays Biochem"},{"key":"10.1016\/j.plipres.2023.101238_bb1305","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.4049\/jimmunol.0901355","article-title":"5-lipoxygenase activating protein signals adipose tissue inflammation and lipid dysfunction in experimental obesity","volume":"184","author":"Horrillo","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.plipres.2023.101238_bb1310","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1096\/fj.201700394R","article-title":"The specialized pro-resolving lipid mediator maresin 1 protects hepatocytes from lipotoxic and hypoxia-induced endoplasmic reticulum stress","volume":"31","author":"Rius","year":"2017","journal-title":"FASEB J"},{"issue":"4","key":"10.1016\/j.plipres.2023.101238_bb1315","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.tips.2018.01.003","article-title":"Specialized Proresolving Mediators: Enhancing Nonalcoholic Steatohepatitis and Fibrosis Resolution","volume":"39","author":"Musso","year":"2018","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.plipres.2023.101238_bb1320","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/jdv.14128","article-title":"A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis","volume":"31","author":"Omland","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.plipres.2023.101238_bb1325","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1096\/fj.02-1157fje","article-title":"Inhibition of 5-lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis","volume":"17","author":"Titos","year":"2003","journal-title":"FASEB J"},{"key":"10.1016\/j.plipres.2023.101238_bb1330","doi-asserted-by":"crossref","first-page":"G553","DOI":"10.1152\/ajpgi.00547.2007","article-title":"Increased susceptibility to exacerbated liver injury in hypercholesterolemic ApoE-deficient mice: potential involvement of oxysterols","volume":"296","author":"Ferre","year":"2009","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.plipres.2023.101238_bb1335","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/hep.23463","article-title":"5-lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor alpha-induced hepatocyte damage in hyperlipidemia -prone ApoE-null mice","volume":"51","author":"Mart\u0131nez-Clemente","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2023.101238_bb1340","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.prostaglandins.2010.03.001","article-title":"Protection from hepatic lipid accumulation and inflammation by genetic ablation of 5-lipoxygenase","volume":"92","author":"Titos","year":"2010","journal-title":"Prostaglandins Other Lipid Mediat"},{"issue":"S1","key":"10.1016\/j.plipres.2023.101238_bb1345","first-page":"1283A","article-title":"MN-001 (tipelukast), a novel, orally bioavailable drug, reduces fibrosis and inflammation and down-regulates TIMP-1, collagen type 1 and LOXL2 mRNA overexpression in an advanced NASH (nonalcoholic steatohepatitis) model","volume":"60","author":"Matsuda","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.plipres.2023.101238_bb1350","author":"American Association for the Study of Liver Diseases (AASLD) and Industry Colloquium"},{"key":"10.1016\/j.plipres.2023.101238_bb1355","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nm.3800","article-title":"LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes","volume":"21","author":"Li","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.plipres.2023.101238_bb1360","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1096\/fj.201500127","article-title":"Importance of adipocyte cyclooxygenase-2 and prostaglandin E2-prostaglandin E receptor 3 signaling in the development of obesity-induced adipose tissue inflammation and insulin resistance","volume":"30","author":"Chan","year":"2016","journal-title":"FASEB J"},{"key":"10.1016\/j.plipres.2023.101238_bb1365","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1089\/jmf.2014.0048","article-title":"Green tea lowers hepatic COX-2 and prostaglandin E2 in rats with dietary fat-induced nonalcoholic steatohepatitis","volume":"18","author":"Chung","year":"2015","journal-title":"J Med Food"},{"key":"10.1016\/j.plipres.2023.101238_bb1370","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09872","article-title":"Celecoxib-mediated attenuation of non-alcoholic steatohepatitis is potentially relevant to redistributing the expression of adiponectin receptors in rats","volume":"8","author":"Zhu","year":"2022","journal-title":"Heliyon."},{"key":"10.1016\/j.plipres.2023.101238_bb1375","doi-asserted-by":"crossref","first-page":"8267","DOI":"10.3390\/ijms23158267","article-title":"COX-2\/sEH dual inhibitor alleviates hepatocyte senescence in NAFLD mice by restoring autophagy through Sirt1\/PI3K\/AKT\/mTOR","volume":"23","author":"Zhang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.plipres.2023.101238_bb1380","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.bbrc.2016.01.186","article-title":"Group IVA phospholipase a(2) deficiency prevents CCl4-induced hepatic cell death through the enhancement of autophagy","volume":"471","author":"Ishihara","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"issue":"9 Pt A","key":"10.1016\/j.plipres.2023.101238_bb1385","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.bbalip.2016.06.004","article-title":"Critical role for cytosolic group IVAphospholipaseA2 in early adipocyte differentiation and obesity","volume":"1861","author":"Pe\u00f1a","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.plipres.2023.101238_bb1390","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1194\/jlr.M066530","article-title":"Major role of adipocyte prostaglandin E2 in lipolysis-induced macrophage recruitment","volume":"57","author":"Hu","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb1395","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/labinvest.2012.128","article-title":"Stimulation of fat accumulation in hepatocytes by PGE\u2082-dependent repression of hepatic lipolysis, \u03b2-oxidation and VLDL-synthesis","volume":"92","author":"Henkel","year":"2012","journal-title":"Lab Invest"},{"key":"10.1016\/j.plipres.2023.101238_bb1400","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.bbrc.2015.12.096","article-title":"Suppressing cyclooxygenase-2 prevents nonalcoholic and inhibits apoptosis of hepatocytes that are involved in the Akt\/p53 signal pathway","volume":"469","author":"Wu","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.plipres.2023.101238_bb1405","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/labinvest.2011.47","article-title":"Oncostatin M produced in Kupffer cells in response to PGE2: possible contributor to hepatic insulin resistance and steatosis","volume":"91","author":"Henkel","year":"2011","journal-title":"Lab Invest"},{"key":"10.1016\/j.plipres.2023.101238_bb1410","article-title":"Celecoxib ameliorates non-alcoholic steatohepatitis in type 2 diabetic rats via suppression of the non-canonical Wnt signaling pathway expression","volume":"9","author":"Tian","year":"2014","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.plipres.2023.101238_bb1415","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s13167-017-0098-2","article-title":"Efficacy of Fenugreek-based bionanocomposite on renal dysfunction and endogenous intoxication in high-calorie diet-induced obesity rat model-comparative study","volume":"8","author":"Konopelniuk","year":"2017","journal-title":"EPMA J"},{"key":"10.1016\/j.plipres.2023.101238_bb1420","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1158\/2159-8290.CD-16-0932","article-title":"Gut microbiota promotes obesity-associated liver cancer through PGE2-mediated suppression of antitumor immunity","volume":"7","author":"Loo","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.plipres.2023.101238_bb1425","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aar8320","article-title":"PGE2 production at sites of tissue injury promotes an anti-inflammatory neutrophil phenotype and determines the outcome of inflammation resolution in vivo","volume":"4","author":"Loynes","year":"2018","journal-title":"Sci Adv"},{"key":"10.1016\/j.plipres.2023.101238_bb1430","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.joca.2017.01.011","article-title":"Adipose stromal cells mediated switching of the pro-inflammatory profile of M1-like macrophages is facilitated by PGE2: in vitro evaluation","volume":"25","author":"Manferdini","year":"2017","journal-title":"Osteoarthr Cartil"},{"key":"10.1016\/j.plipres.2023.101238_bb1435","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1177\/2042098617690485","article-title":"Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications","volume":"8","author":"Fanelli","year":"2017","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.plipres.2023.101238_bb1440","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/1753-0407.12358","article-title":"Soluble epoxide hydrolase: a potential target for metabolic diseases","volume":"8","author":"He","year":"2016","journal-title":"J Diabetes"},{"issue":"Suppl","key":"10.1016\/j.plipres.2023.101238_bb1445","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1194\/jlr.R800038-JLR200","article-title":"Arachidonic acid cytochrome P450 epoxygenase pathway","volume":"50","author":"Spector","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb1450","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1073\/pnas.1422590112","article-title":"Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: role for omega-3 epoxides","volume":"112","author":"Lopez-Vicario","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.plipres.2023.101238_bb1455","doi-asserted-by":"crossref","first-page":"8267","DOI":"10.3390\/ijms22158267","article-title":"Differential effects of 17,18-EEQ and 19,20-EDP combined with soluble epoxide hydrolase inhibitor t-TUCB on diet-induced obesity in mice","volume":"22","author":"Yang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.plipres.2023.101238_bb1460","doi-asserted-by":"crossref","first-page":"14189","DOI":"10.1074\/jbc.M113.458414","article-title":"Soluble epoxide hydrolase deficiency or inhibition attenuates diet-induced endoplasmic reticulum stress in liver and adipose tissue","volume":"288","author":"Bettaieb","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2023.101238_bb1465","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.prostaglandins.2016.07.002","article-title":"Characterization of the cytochrome P450 epoxyeicosanoid pathway in non-alcoholic steatohepatitis","volume":"125","author":"Wells","year":"2016","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.plipres.2023.101238_bb1470","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110162","article-title":"The cytochrome P450 epoxygenase pathway regulates the hepatic inflammatory response in fatty liver disease","volume":"9","author":"Schuck","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.plipres.2023.101238_bb1475","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12791","article-title":"Epoxyeicosatrienoic acids alleviate methionine-choline-deficient diet-induced non-alcoholic steatohepatitis in mice","volume":"90","author":"Wang","year":"2019","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.plipres.2023.101238_bb1480","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.plipres.2004.10.001","article-title":"Epoxide hydrolases: their roles and interactions with lipid metabolism","volume":"44","author":"Newman","year":"2005","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.plipres.2023.101238_bb1485","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2174\/1874467214666210920104352","article-title":"A clinical perspective of soluble epoxide hydrolase inhibitors in metabolic and related cardiovascular diseases","volume":"15","author":"Verma","year":"2022","journal-title":"Curr Mol Pharmacol"},{"key":"10.1016\/j.plipres.2023.101238_bb1490","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1084\/jem.192.8.1197","article-title":"Novel functional sets of lipid-derived mediators with anti-inflammatory actions generated from omega-3fatty acids via cyclooxygenase2-non steroidal anti-inflammatory drugs and transcellular processing","volume":"192","author":"Serhan","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.plipres.2023.101238_bb1495","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.bbalip.2010.08.002","article-title":"Specialized pro-resolving lipid mediators in the inflammatory response: an update","volume":"1801","author":"Bannenberg","year":"2010","journal-title":"Biochim Biophys Acta"},{"issue":"9 Pt A","key":"10.1016\/j.plipres.2023.101238_bb1500","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.bbalip.2016.06.002","article-title":"Resolvin D1 protects the liver from ischemia\/reperfusion injury by enhancing M2 macrophage polarization and efferocytosis","volume":"1861","author":"Kang","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.plipres.2023.101238_bb1505","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1080\/15548627.2015.1078958","article-title":"Activation of autophagy in macrophages by pro-resolving lipid mediators","volume":"11","author":"Prieto","year":"2015","journal-title":"Autophagy"},{"key":"10.1016\/j.plipres.2023.101238_bb1510","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf7483","article-title":"Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses","volume":"8","author":"Chiurchi\u00f9","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.plipres.2023.101238_bb1515","doi-asserted-by":"crossref","first-page":"C1141","DOI":"10.1152\/ajpcell.00351.2012","article-title":"Diversity of lipid mediators in human adipose tissue depots","volume":"304","author":"Cl\u00e0ria","year":"2013","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.plipres.2023.101238_bb1520","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12944-021-01518-5","article-title":"Low serum Maresin-1 levels are associated with non-alcoholic fatty liver disease: a cross-sectional study","volume":"20","author":"Fang","year":"2021","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.plipres.2023.101238_bb1525","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1172\/JCI124219","article-title":"A maresin 1\/ROR\u03b1\/12-lipoxygenase autoregulatory circuit prevents inflammation and progression of nonalcoholic steatohepatitis","volume":"129","author":"Han","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.plipres.2023.101238_bb1530","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cmet.2015.05.003","article-title":"Lipoxin A4 attenuates obesity-induced adipose inflammation and associated liver and kidney disease","volume":"22","author":"B\u00f6rgeson","year":"2015","journal-title":"Cell Metab"},{"key":"10.1016\/j.plipres.2023.101238_bb1535","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ijo.2017.226","article-title":"Maresin 1 mitigates liver steatosis in Ob\/Ob and diet-induced obese mice","volume":"42","author":"Laiglesia","year":"2018","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.plipres.2023.101238_bb1540","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1096\/fj.201600859R","article-title":"Maresin 1 improves insulin sensitivity and attenuates adipose tissue inflammation in Ob\/Ob and diet-induced obese mice","volume":"31","author":"Mart\u00ednez-Fern\u00e1ndez","year":"2017","journal-title":"FASEB J"},{"key":"10.1016\/j.plipres.2023.101238_bb1545","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1096\/fj.13-235614","article-title":"Resolvin D1 primes the resolution process initiated by calorie restriction in obesity-induced steatohepatitis","volume":"28","author":"Rius","year":"2014","journal-title":"FASEB J"},{"key":"10.1016\/j.plipres.2023.101238_bb1550","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.mce.2014.04.012","article-title":"Resolvin D1 reduces ER stress-induced apoptosis and triglyceride accumulation through JNK pathway in HepG2 cells","volume":"39","author":"Jung","year":"2014","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.plipres.2023.101238_bb1555","doi-asserted-by":"crossref","first-page":"46754","DOI":"10.1038\/srep46754","article-title":"Post-treatment with Protectin DX ameliorates bleomycin-induced pulmonary fibrosis and lung dysfunction in mice","volume":"7","author":"Li","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.plipres.2023.101238_bb1560","first-page":"3","article-title":"17(R)-resolvin D1 ameliorates bleomycin-induced pulmonary fibrosis in mice","author":"Yatomi","year":"2015","journal-title":"Physiol Rep"},{"key":"10.1016\/j.plipres.2023.101238_bb1565","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.3892\/etm.2014.1641","article-title":"Resolvin E1 reduces hepatic fibrosis in mice with Schistosoma japonicum infection","volume":"7","author":"Qiu","year":"2014","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.plipres.2023.101238_bb1570","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1016\/j.biocel.2013.09.018","article-title":"Resolvin D1 inhibits TGF-\u03b21-induced epithelial mesenchymal transition of A549 lung cancer cells via lipoxin A4 receptor\/formyl peptide receptor 2 and GPR32","volume":"45","author":"Lee","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.plipres.2023.101238_bb1575","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/SHK.0000000000000446","article-title":"Maresin 1 inhibits epithelial-to-mesenchymal transition in vitro and attenuates bleomycin induced lung fibrosis in vivo","volume":"44","author":"Wang","year":"2015","journal-title":"Shock"},{"key":"10.1016\/j.plipres.2023.101238_bb1580","doi-asserted-by":"crossref","first-page":"2438247","DOI":"10.1155\/2017\/2438247","article-title":"Maresin 1 mitigates high glucose-induced mouse glomerular mesangial cell injury by inhibiting inflammation and fibrosis","volume":"2017","author":"Tang","year":"2017","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.plipres.2023.101238_bb1585","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.32647","article-title":"Essential lipid autacoids rewire mitochondrial energy efficiency in metabolic dysfunction-associated fatty liver disease","volume":"77","author":"L\u00f3pez-Vicario","year":"2023","journal-title":"Hepatology."},{"key":"10.1016\/j.plipres.2023.101238_bb1590","doi-asserted-by":"crossref","first-page":"L904","DOI":"10.1152\/ajplung.00370.2014","article-title":"Proresolving actions of a new resolvin D1 analog mimetic qualifies as an immunoresolvent","volume":"308","author":"Orr","year":"2015","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.plipres.2023.101238_bb1595","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.yjmcc.2015.04.003","article-title":"Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function","volume":"84","author":"Kain","year":"2015","journal-title":"J Mol Cell Cardiol"},{"issue":"13","key":"10.1016\/j.plipres.2023.101238_bb1600","first-page":"345","article-title":"Experimental pharmacotherapy for dry eye disease: a review","volume":"23","author":"] Baiula M, Spampinato S.","year":"2021","journal-title":"J Exp Pharmacol"},{"key":"10.1016\/j.plipres.2023.101238_bb1605","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.plipres.2023.101238_bb1610","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.838782","article-title":"Formation, Signaling and occurrence of specialized pro-resolving lipid mediators-what is the evidence so far?","volume":"13","author":"Schebb","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["Progress in Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163782723000280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163782723000280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T17:23:09Z","timestamp":1779470589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163782723000280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":322,"alternative-id":["S0163782723000280"],"URL":"https:\/\/doi.org\/10.1016\/j.plipres.2023.101238","relation":{},"ISSN":["0163-7827"],"issn-type":[{"value":"0163-7827","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances","name":"articletitle","label":"Article Title"},{"value":"Progress in Lipid Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.plipres.2023.101238","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101238"}}